LTS Nutraceuticals, Inc. (the "Company") (OTCBB: LTSN), a developer and manufacturer of nutritional and personal care products, today announced that a clinical study was done on BioCalth® product that confirmed BioCalth's effectiveness in repairing bone deterioration. The study was conducted by Dr. Jing Liang MD PhD, Associate Professor of Molecular & Medical Pharmacology at the David Geffen School of Medicine, UCLA. Dr. Liang has over 20 years of experience in pharmaceutical research and development.

BioCalth® is a unique, patented Calcium L-Threonate supplement that was clinically tested to determine whether BioCalth could improve bone density and encourage the formulation of cartilage and collagen to strengthen bones.* Osteogenesis is the formation and development of bone. Bone is a dynamic tissue that is constantly being reshaped by osteoblasts, in charge of production of osteoid matrix and their mineralization. Osteoblast cells tend to decrease with age, affecting the balance of formation and absorption in the bone tissue, often causing bone fractures.

Dr. Liang and her team determined that BioCalth not only increased osteoblast numbers and enhanced mineralization of osteoids; BioCalth also was absorbed by the osteoblasts five times more than other calcium products that were compared to. Study also showed that BioCalth increased osteoid collagen and made alkaline phosphatase activated which is in charge of transforming osteoid into mineralized or calcified extracellular matrix or new bone tissue.

"We continue to study the effects of BioCalth, as the product could potentially benefit over 40 million Americans that have an increased risk of bone fracture," commented Dr. Liang. "We believe that BioCalth can be a candidate for therapeutic medication for Osteoporosis, Osteogenesis Imperfecta and other disease induced problems, bone mass loss or pain due to bone mass loss and even supplementary treatment after teeth-implants."

"BioCalth is only now being introduced to the U.S. market and we believe with this research, the products' effectiveness, compared to other leading brands of calcium products, has been validated and we can expect to see a demand for BioCalth products throughout the retail channels," commented CEO of LTS Nutraceuticals, Jerry Rayman.

*These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

About LTS Nutraceuticals, Inc.

Headquartered in Ft. Lauderdale, FL, LTS Nutraceuticals, Inc. develops, manufactures, markets and distributes an expanding line of unique, high-quality vitamins, vitamin boosters, dietary supplements and nutraceuticals. The products are sold throughout North America through two marketing channels: direct selling utilizing Inline Marketing? to introduce products to the consumer and marketing products through national retail, drug and grocery chains and club stores.

More information about the Company, visit: www.LTSNinc.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation,statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of LTS Nutraceuticals, Inc. can be found in the filings of LTS Nutraceuticals, Inc. with the U.S. Securities and Exchange Commission.

LTS Nutraceuticals, Inc.
Investor Relations, 954-858-8020
ir@ltsninc.com